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Microglia, the resident immune cells of the brain, have multiple functions in physiological
and pathological conditions, including Alzheimer’s disease (AD). The use of primary
microglial cell cultures has proved to be a valuable tool to study microglial biology under
various conditions. However, more advanced transfection methodologies for primary
cultured microglia are still needed, as current methodologies provide low transfection
efficiency and induce cell death and/or inflammatory activation of the microglia. Here, we
describe an easy, and effective method based on the Glial-Mag method (OZ Biosciences)
using magnetic nanoparticles and a magnet to successfully transfect primary microglia
cells with different small interfering RNAs (siRNAs). This method does not require
specialist facilities or specific training and does not induce cell toxicity or inflammatory
activation. We demonstrate that this protocol successfully decreases the expression of
two key genes associated with AD, the triggering receptor expressed in myeloid cells 2
(TREM2) and CD33, in primary microglia cell cultures.
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INTRODUCTION
Microglia are the resident tissue macrophages of the central nervous system (CNS) where
they survey for insults that may affect the homeostasis of the system (Kettenmann et al., 2011;
Boche et al., 2013). They play several roles under physiological conditions, including synaptic
pruning (Schafer et al., 2012; Um, 2017), but are also important during neurodegenerative
diseases (Hirsch and Hunot, 2009; Rayaprolu et al., 2013; Nalls et al., 2014; Ulrich et al.,
2014; Sims et al., 2017; Kang et al., 2018b). In the case for Alzheimer’s disease (AD), early
studies in the 1990s showed the presence of activated immune cells in the brains of deceased
people affected by AD (Eikelenboom et al., 1994), which suggested the hypothesis that the
neuroinflammatory response plays a detrimental role during the disease progression. This
hypothesis has been supported by many other reports, including some recent genome-wide
association studies (GWAS) showing that several polymorphisms in innate immune genes
are risk factors to develop AD (Rayaprolu et al., 2013; Mhatre et al., 2015; Sims et al., 2017).
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Mechanistic studies in microglia cells heavily depends on
in vitro approaches using different microglia cells lines (e.g., BV2,
CHME3), induced pluripotent stem cell (iPS) derived cells
or rodent primary microglia cell cultures. Cell lines are
convenient because they do not require isolation and can be
expanded indefinitely to provide high yields. However, during
immortalization and repeated passaging, they may have acquired
different features that are not present under physiological
conditions in primary microglia cells (Butovsky et al., 2014).
Working with iPS cells is also a very valuable tool due to their
capabilities to be transformed into different cell types, including
microglia cells. On the other hand, the process for expansion
and transformation of iPS cells into microglia cells is a laborious
and complicated procedure, with several different protocols to
follow in the literature (Muffat et al., 2016; Brownjohn et al.,
2018).
Hence, working with primary microglia cell cultures is
important. However, working with primary microglia cell
cultures presents challenges. One of the main limitations is
the low yield produced from each animal and their limited
survival time period in the absence of astrocytes. Also, primary
microglia cell cultures are difficult cells to transfect, providing
low efficiency of transfection and also are quite vulnerable
to death when using traditional methods of transfection. One
way to solve this problem has been to generate different
transgenic mouse lines, as in the case of triggering receptor
expressed in myeloid cells 2 (TREM2; Turnbull et al., 2006;
Cheng et al., 2018; Filipello et al., 2018). Primary microglia
cells are then isolated from these mice. However, this process
is expensive and takes several months before you obtained
the desired transgenic line. An alternative to generation of
transgenic mice has been the use of transduction systems to
overexpress or silence the expression of different protein targets.
In particular, the use of lentiviral vectors has proven to be
effective for this purpose (Masuda et al., 2013). However,
the whole process can be challenging and requires the use
of specific material (like class II security hoods) and special
training for different type of tasks such as design of the
virus’ sequence, choosing the right bacterial strain to avoid
genomic rearrangements while amplifying the viral vector,
stability of your viral stock to freeze and thaw cycles, efficiency
of transduction depending on the concentration of your virus
(virus tittering), or the usage of different reagents (for instance
polybrene or fibronectin) to decrease the repulsive charges of
the virus with the cell membranes to increase the transduction
efficiency.
Here, we describe a simple method to knockdown the
expression of different genes in primary microglia by using
small interfering RNA (siRNA) and the MagnetofectionTM
principle patented byOZ Biosciences as amethod of transfection.
The MagnetofectionTM method allow us to associate nucleic
acids (in this case siRNA), with specific magnetic nanoparticles
(made of iron oxide which is fully degradable). The resulting
molecular complexes are then concentrated and transported
into cells through an appropriate magnetic field. Therefore,
the exploitation of a magnetic force exerted upon the
siRNAs allows a very rapid concentration of the entire
applied siRNA dose on cells, so that 100% of the cells
get in contact with a significant vector dose and promotes
cellular uptake. The cellular uptake of the genetic material
is accomplished by endocytosis and pinocytosis, two natural
biological processes. Consequently, membrane architecture and
structure remain intact in contrast to other physical transfection
methods that damage, create hole or electroshock the cell
membranes.
To illustrate the use of this method in primary microglia we
have knocked down the expression of TREM2 and CD33, two
important genes whose mutations are considered a risk factor to
develop AD (Griciuc et al., 2013; Colonna and Wang, 2016).
MATERIALS AND METHODS
Reagents
LPS from Salmonella enterica serotype typhimurium (Sigma,
catalog number L6511) was used for this study. Isolectin GS-IB4
from Griffonia simplicifolia (Alexa Fluorr 568 conjugate)
was purchased from Thermo Fisher (catalog number I21412).
Glial-Mag kit was purchased from OZ Biosciences (catalog
number KGL00250). The protocol used is based on the
manufacturer’s recommendation, which we have optimized for a
24-well plate format (Supplementary Figure S1). The different
siRNAs (positive—siGLO— and negative controls—non-
targeting— and siTREM2 and siCD33) were purchased from
Dharmacon (Horizon) and their sequences and catalogs numbers
are provided in Table 1. A complete list of primers (ordered
through Sigma Aldrich) with their sequences is provided in
Table 2.
Animals
Two to five days-old wild-type mice (C57BL/6 background) and
rats (Wistar) were obtained from Charles River Laboratories. All
experiments were performed in accordance with the UKAnimals
(Scientific Procedures) Act (1986) and were approved by the
Cambridge University local ethical committee.
TABLE 1 | Sequence and catalog numbers for the different small interfering RNAs
(siRNAs).
siRNA Catalog number Sequence
siRNA non-targeting (1) D-001810-10 UGGUUUACAUGUCGACUAA
siRNA non-targeting (2) D-001810-10 UGGUUUACAUGUUGUGUGA
siRNA non-targeting (3) D-001810-10 UGGUUUACAUGUUUUCUGA
siRNA non-targeting (4) D-001810-10 UGGUUUACAUGUUUUCCUA
Mouse siCD33 (1) J-047562-09 CAAUAAGAGACCCGGGACA
Mouse siCD33 (2) J-047562-10 GCUCAAUGUUACCCGGAAA
Mouse siCD33 (3) J-047562-11 GGAGCUUGCUGUUUAGGCA
Mouse siCD33 (4) J-047562-12 GAGAACCUUUUGUGAGAUA
Mouse siTREM2 (1) J-040918-09 CGGAGGUACGUGAGAGAAU
Mouse siTREM2 (2) J-040918-10 GGUCAGAGGGCUGGACUGU
Mouse siTREM2 (3) J-040918-11 CCUGCGUUCUCCUGAGCAA
Mouse siTREM2 (4) J-040918-12 CUGAGUGGGAGGAGAACUA
Rat siTREM2 (1) J-082332-09 CAGAAUGGGAGCACGGUCA
Rat siTREM2 (2) J-082332-10 CGUCUGUACUUUGGACAUU
Rat siTREM2 (3) J-082332-11 UAUCCCGGGAGCAGGAAUA
Rat siTREM2 (4) J-082332-12 CCGAGGAGUCAGAGAGUUU
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TABLE 2 | Sequence for primers.
Name of Forward Reverse
gene sequence (5′→3′) sequence (5′→3′)
Actb (mouse) CCACACCCGCCACCAGTTCG CCCATTCCCACCATCACACC
Actb (rat) AAGACCTCTATGCCAACAC TGATCTTCATGGTGCTAGG
Cd33 (mouse) ATGAGAGAGCTGGTCCTGGT CCCATGTGCACTGACAGCTT
Il1-β (mouse) GTGCTGTCGGACCCATATGA AGGCCACAGGTATTTTGTCGT
Nos2 (mouse) CTGGGGCAGTGGAGAGATTT TTGTCTCTGGGTCCTCTGGT
Tnfα (mouse) GGTGCCTATGTCTCAGCCTC ACTGATGAGAGGGAGGCCAT
Trem2 (mouse) TCATCTCTTTTCTGCACTTC TCATAAGTACATGACACCCTC
Trem2 (rat) AAACAAGATCTGACACAAGG CGTCATAAGTACATGACACC
Generation of Primary Microglia Cultures
From Postnatal Mouse and Rats
Primary microglia cultures were prepared from mice and rat
pups at postnatal day P1–5 which were sacrificed by decapitation.
Brains were removed in ice-cold Ca2+- and Mg2+-free Hanks
Buffered Salt Solution (HBSS, Invitrogen) containing 10 µg/ml
gentamicin (Sigma). Cortical hemispheres were dissected and
meninges, blood vessels as well as white matter were removed.
Tissue was cut into small pieces and transferred to pre-warmed
HBSS containing 0.17% trypsin (37◦C), chopped thoroughly and
incubated for 15–20 min at 37◦C. Supernatant was removed and
the remaining trypsin was neutralized by addition of Dulbecco’s
Modified Eagle’s Medium (DMEM, Invitrogen) supplemented
with 10% fotal bovine serum (FBS) and gentamicin (10 µg/ml)
in mice. In the case of rats, we added also 1–2 mg of
Deoxyribonuclease from bovine pancreas (Sigma) in 25 ml of
DMEM supplemented with 10% FBS and gentamicin (10µg/ml).
Tissue was mechanically dissociated by repeated trituration
through a 10 ml and 5 ml sterile serological pipettes and finally
through a 1 ml pipette tip (pipetted up and down 20 times
with each one of the serological pipettes), leaving the suspension
undisturbed for 1 min before collecting the supernatant. The
supernatant was centrifuged at 150 g for 7 min at room
temperature. We discarded the supernatant and resuspended
the pellet in fresh media. The cell suspension was then filtered
using first a 100 µm cell strainer and then a 40 µm cell strainer
(BD Biosciences, San Jose, CA, USA). Both cell strainers were
previously moistened with 2 ml of complete media to facilitate
the filtering process. The cell suspension was centrifuged at 150 g
for 7 min at room-temperature (RT). Supernatant was discarded,
and the cell pellet was resuspended in DMEM supplemented with
10% FBS and 10 µg/ml gentamicin (Sigma) and seeded onto
T75 flask (Nunc) coated with 0.0005% poly-L-lysine (Sigma) in
PBS at a ratio of 3–4 pups (mouse) or 1 pup (rat) per T75 cell
culture flask. After 24 h, the T75 flask was carefully tapped to
dislodge sedimentary cell debris, and medium was exchanged
(20 ml/flask). Cultures were maintained at 37◦C in a humidified
atmosphere of 5% CO2 and allowed to mature in vitro for
7–14 days before transfection. Microglial cells were harvested
from confluent astrocyte monolayers, 14 days after the initial
seeding, by a combination of tapping the side of the culture flask
and gently vortexed for∼1-min supernatant containing detached
microglial cells was collected and centrifuged at 150 g for 7 min
at room temperature. These microglial cells found were plated
into 24-well plates in conditioned media to a ratio 1:3 (media
from flask: fresh media), coated with 0.0005% poly-L-lysine, at
a density of 200,000 cells in 400 µl per well. Experiments were
performed 48 h after the final plating.
Primary Cerebellar Granule Cells (CGCs)
Cultures From Mouse and Rat Pups
Primary mixed neuronal/glial cultures were prepared from
cerebella of postnatal day 3–5 mice or rat pups as previously
described (Kinsner et al., 2005). Briefly, pups were killed by
decapitation and brains were quickly removed and placed in
ice-cold HBSS containing 10 µg/ml gentamicin (Sigma). Then,
the cerebella were separated from the brainstem, and meninges
were removed. The tissue was transferred into pre-warmed
Versene solution (37◦C, Invitrogen), cut into small pieces
and incubated for 5 min at 37◦C, 5% CO2. Tissue was then
mechanically dissociated using a sterile plastic pasteur pipettes,
and then, with P1000 tips of decreasing aperture size. After
each dissociation step, dissociated cells present in the Versene
solution were added in pre-warmed DMEM supplemented with
5% horse serum, 5% FBS, 5 mM 4-(2-Hydroxyethyl) piperazine-
1-ethanesulfonic acid (HEPES), 20 mM KCl, 2 mM L-glutamine,
13 mM glucose and 10µg/ml gentamicin (all Sigma). Dissociated
cells resuspended in supplemented DMEM were centrifuged at
150 g for 7 min at RT. The cell-suspension was passed through
a 40 µm cell-strainer (BD Biosciences, San Jose, CA, USA) and
cells were seeded on 0.001% poly-L-lysine-coated (Sigma) glass
coverslips onto 24-well plates (Nunc) at a density of 2.5 × 105
cells/cm2. The culture medium (500µl/well) was exchanged after
24 h and cultures allowed to mature in vitro for 7–10 days before
transfection.
Transfection of siRNA in Murine Primary
Microglia Using the OZ Bioscience
Magnetic Plate Technology
We followed the manufacturer’s recommendations with a few
modifications (Supplementary Figure S1). The amounts used
here refer to a 24-well plate format. In one microcentrifuge tube
we added 0.6 µl of siRNA (stock concentration is 20 µM) and
we mixed by vortexing with 100 µl of DMEM without serum or
antibiotics. The contents of this tube were added to a new tube
with 0.4 µl of Glial-Mag where the contents were mixed gently
by pipetting up and down 4–5 times. The mix was incubated at
room temperature for 20 min. During this incubation period, we
removed 100 µl of media per well from the plates where primary
cells were seeded using the previously described complete media
to assure a final volume of 400 µl of media per well. The content
of the microcentrifuge tube was then added drop by drop to
each well together with 5 µl of Glial boost 100×, the second
component in the Glial-Mag kit. We placed the culture plate
inside of the cell incubator on top the magnetic plate provided
by the manufacturer for 30 min. Afterwards, we removed the
magnetic plate and left the cells in the incubator for 3 h at 37◦C.
We then exchanged the media for conditioned media saved from
microglia co-cultured with astrocytes (ratio 1:3 fresh media:
old media; in the case of pure microglial cultures) or complete
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media as described above (in the case of cerebellar granule cell
(CGC) cultures) and waited for 48 h before we performed the
experiments. A description of the different steps for transfection
are included in Supplementary Figure S1. The different siRNAs
used for this study were siGLO Green (positive control for
delivery #D-001630-01) ON-TARGETplus Non-targeting
Pool (#D-001810-10), ON-TARGETplus Mouse Cd33 siRNA
(#L-047462-01), ON-TARGETplus Mouse Trem2 siRNA
(#L-040918-01) and ON-TARGETplus Rat Trem2 siRNA
(#L-082332-02). The sequences of the different siRNAs are
provided in Table 1.
Quantification of Cell Numbers in CGCs
and Pure Microglia Cultures and Analysis
of the Percentage of Cells Transfected
With siGLO
Following the same protocol of transfection as with primary
cortical microglia cells, 3 h and 30 min after transfection
CGC cultures were washed once in PBS and fixed with 4%
paraformaldehyde (PFA, in PBS, pH 7.4), and washed three
more times with PBS. Then, fixed cultures were stained with
the nuclear dye Hoechst 33342 (5 µg/mL) and 568-tagged
isolectin-B4 (1 µg/mL) was used to identify microglia. Healthy
and apoptotic (chromatin-condensed) neurons were recognized
by their distinct nuclear morphology, whereas bigger and more
diffuse nuclei stained byHoechst 33342 were scored as astrocytes.
siGLO was used to assess the % of cells that were transfected.
The % of siGLO positive cells was measured as 100× (number
of microglia or astrocytes or neurons that contain siGLO/total
number of microglia or astrocytes or neurons).
Similarly, both CGC cultures and pure microglia cultures
were kept inside the incubator 48 h after transfection. Then,
cells were stained with Hoechst 33342, and 568-tagged isolectin-
B4, as previously indicated. In all the experiments, four
microscopic fields/well (between 150 and 250 neurones per field)
in 1–2 wells/condition were quantified for a single experiment.
Total cell densities and % of siGLO positive cells were evaluated
using a Leica DMI6000 CS microscope and cell densities were
quantified using the cell counter plugin on ImageJ software.
RT-qPCR Analysis
Total RNA was extracted using the QIAzol Reagent (QIAGEN)
following the manufacturer’s instructions. Using the RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientific, UK), 1 µg
of the total RNA was transformed into cDNA. RT-qPCR was
performed using the MESA BLUE SYBRr Assay (Eurogentec,
UK). Results were calculated using delta Ct method and
represented as absolute values with arbitrary units. β-actin
was used as the housekeeping gene. The primer sequences are
provided in Table 2.
Preparation of Labeled Neuronal Debris
To generate stained neuronal debris, mouse and rat CGCs
originated from P3 to P5 were used (which are 90% neurons).
Cells were washed twice with PBS and after the second
wash, 100 µl of PBS was left in the well (24-well plate
format) into which the cells were scraped. Then the cells were
passed 5–10 times through a 27G syringe needle. After that,
we incubated the neuronal debris with tetramethylrhodamine
(TAMRA; 50µM) for 20min at room temperature with agitation
and protection from light. Excess of TAMRA was removed using
a 5 kDa spin column (spin columns were previously left in the
hood for 15 min under UV light). Columns were washed twice
with PBS (200 µl) at 8,050 g for 10 min before stained debris
(200 µl) with 200 µl of PBS were added and centrifuged at 8,050
g for 10 min twice. After each centrifugation, PBS containing
free TAMRA was discarded and replaced with 200 µl of fresh
PBS. After the second wash stained debris from the column
was collected and protein concentration was measured using
PierceTM BCA protein assay kit (ThermoFisher Scientific).
Analysis of Phagocytosis by Flow
Cytometry
Microglial phagocytic activity was assessed by evaluating the
uptake rate of TAMRA-stained neuronal debris as previously
shown (Hornik et al., 2016) with slight modifications. Briefly,
pure microglia cultures were incubated with TAMRA-stained
neuronal debris (60 µg/ml) for 1 h inside the cell incubator.
The culture media was then removed and 100 µl of 1×
trypsin (0.1%) was added to each well and incubated for 5 min
in the incubator. To stop the reaction, 500 µl of culture
medium was added. Cells were collected and transferred to a
microcentrifuge tube and centrifuged for 5 min at 150 g at
room temperature. The supernatant was removed, and cells were
fixed with 50 µl of 4% PFA (in PBS) for 15 min at room
temperature using agitation. After centrifugation at 150 g for
5 min at room temperature, PFA was removed and cells were
resuspended in 100 µl of cold PBS. Samples were kept on
ice before the analysis by flow cytometry. The FL3 (excitation
640 nm, emission >670 nm; red; TAMRA in neuronal debris)
fluorescence of the cells was measured using a BD Accuri
C6 flow cytometer (BD Biosciences, San Jose, CA, USA). Cells
not treated with TAMRA-stained neuronal debris were used
to set the flow cytometry gates. The average of the TAMRA-
positive fluorescence in cells treated with non-targeting siRNA
was determined and compared to the fluorescence of cells
treated with the TREM2 siRNA. Values were normalized to
the fluorescence of cells treated with non-targeting siRNA and
TAMRA-stained neuronal debris. Flow cytometry analysis was
performed using BD Accuri C6 software.
Quantification of IL-6 Release Into the
Media
Supernatants of the different cell culture treatments were
collected and fast freeze on dry ice and stored at −80◦C until
further use. We analyzed the content of IL-6 in the media by
using theMouse IL-6 ELISAMAXTM Deluxe Sets (BiolegendCat.
No. 431304) following manufacturer’s instructions.
Statistical Analysis
Data normality and homogeneity of variances were analyzed
using the Shapiro-Wilk and the Levene’s tests, respectively. All
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data were normally distributed. Results were tested for statistical
significance using one-way ANOVA analysis of the variance
with a Tukey’s multiple comparisons post hoc analysis using
the Statgraphics or GraphPad Prism software. For those results
that do not show homogeneity of variance, an unequal variance
two-tailed t test, (Welch’s t test) was used. P < 0.05 was
considered statistically significant. The number of independent
experiments and statistical test used is described in the relevant
figure legends. Each independent experiment represents a
separate mouse or rat litter.
RESULTS
Delivery of siRNA and Efficacy of
Knockdown in Primary Microglia Cells
Our first experiment was to assess the amount of Glial-Mag
necessary to obtain a satisfactory delivery rate of a fluorescently-
labeled RNA oligonucleotide (siGLO Green 6-FAM, henceforth
referred as siGLO) into the primary microglial cells. For that
reason, in a 24-well plate format we added different volumes of
Glial-Mag together with a fixed dose of siGLO (same dose as
used with siRNA TREM2 or siCD33) to the primary microglial
cells. Three hours and 30 min after treatment with siGLO, cells
were collected to analyze the degree of delivery of siGLO by
flow cytometry (Figures 1A,B). We observed a similar degree of
delivery at all doses tested (volume per well of Glial-Mag added:
0.4 µl/500 µl, 0.6 µl/500 µl, 0.7 µl/500 µl and 0.8 µl/500 µl),
resulting in 83%–93% of the microglia containing siGLO at this
time point (Figures 1A,B). Subsequently, all the experiments
were conducted with the lowest dose of Glial-Mag (0.4 µl/500 µl
per well).
We then used specific siRNAs against either TREM2 or
CD33, combined with the magnetic nanoparticles of the
Glial-Mag medium, and incubated with the microglia on
top of a magnet to enable penetration of the siRNAs,
as described in the ‘‘Materials and Methods’’ section and
Supplementary Figure S1. We then analyzed the efficacy of
knockdown by siTREM2 and siCD33 at the mRNA level
measured by RT-qPCR in mouse primary cortical microglia.
In both cases, we observed that the mRNA level was
decreased by about 60%, 48 h after siRNA transfection
(Figures 1C,D).
Effect of Protocol on Microglial Survival
and Inflammatory Response
An effective transfection protocol for primary microglia cells
should aim to minimize the impact over the survival of the
cells in the culture through stress, and neither should induce
per se an inflammatory response or prime it. We wanted to
know if our method of transfection meets these criteria. After
7–10 days in culture, primary cultures were transfected in the
absence or presence of siRNA non-targeting (siNT) and we
tested the effect of transfection over survival in primary cortical
microglia cells (48 h post-transfection, Figures 2A,B) and also
in neuronal/glia mixed cultures obtained from the cerebellum
(3 h 30 min post-transfection Supplementary Figures S2A,B
FIGURE 1 | Small interfering RNA (siRNA) delivery and efficiency transfection
analysis using the Glial-Mag technology. (A,B) Assessment of the delivery of
siGLO reagent through flow cytometry represented by dot plots and histogram
into mouse primary cortical microglia cells using increasing amounts of
Glial-Mag. Analysis of triggering receptor expressed in myeloid cells 2
(TREM2; C) and CD33 (D) gene expression after transfection with specific
siRNA measured by room-temperature (RT)-qPCR. Results are presented as
mean (B–D) ± SD (B,C). Data are from one (A,B) or five (C) or three (D)
independent experiments. ∗∗P < 0.01 and ∗∗∗P < 0.001. All analyses were
performed using two-tailed Welch’s t-test.
and 48 h post-transfection, Figures 2C,D). For this reason, we
analyzed microglial density for the primary cortical microglia
cells and also neuronal, microglia and astrocyte densities in
neuronal/glial mixed cultures (Supplementary Figures S2A–D)
of wild type mouse and rat. In primary cortical microglial
cultures, we found no negative effect over survival in both species
48 h after transfection (Figures 2A,B). In the neuronal/glial
mixed cultures we found no effect over the neuronal population
(Figure 2C) but we could observe a slight change in the
density of microglia (increase in mouse and a decrease in
rats compared to naïve microglia) 48 h after transfection
(Figure 2D).
We also transfected our primary neuronal/glia mixed cultures
with siGLO for 3 h and 30 mins in mouse and rat (shown
here as green dots, Supplementary Figures S2B–D) and we
observed that it was efficiently incorporated not only in the
cytoplasm of microglia cells (≈80% of total primary microglia
were siGLO positive, as indicated by IB4 staining), but also in
astrocytes (≈40%–50% of total primary astrocytes were siGLO
positive, as indicated by higher nuclei morphology shown by
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 September 2018 | Volume 12 | Article 313
Carrillo-Jimenez et al. siRNA Magnetofection in Primary Microglia
FIGURE 2 | Effect of Glial-Mag technology over cell survival and glia
proliferation upon 48 h transfection in primary cortical microglial and cerebellar
granule cells (CGCs) primary cultures in wild type mouse and rats.
(A) Representative images and insets showing microglia (IB4, green), PI (as a
necrotic marker, red) and nuclei (Hoechst, blue) staining in cortical primary
cultures from wild type mouse and rat transfected with or without siRNA
non-targeting (siNT). (B) Quantitative analysis showing microglial density in
mouse and rat cortical primary cultures transfected with or without siNT.
(C,D) Quantitative analysis showing neuronal (C) and microglia and astrocyte
density (D) in mouse and rat CGC primary cultures transfected with or without
siNT. (E) Analysis of IL-6 release into the media in naïve and 48 h transfected
siNT treated cells ± LPS treatment (8 h; 10 ng/ml). Results are presented as
mean ± SEM (B–D) and ± SD (E). Quantitative analysis of cell numbers in
(B–D) represent four microscopic fields (mouse) or four microscopic fields in
duplicate or triplicate (rat) for each condition from three independent
experiments for both mouse and rat. Data are from five (for naïve and siNT)
and for three (naïve + LPS and siNT + LPS) independent experiments in (E).
All analyses were performed using one-way ANOVA and Tukey’s multiple
comparisons post hoc test. n.s stands for non-significant. ∗P < 0.05 and
∗∗P < 0.01 compared to naïve condition. Scale bar, 50 µm.
Hoechst staining) and neurons (only ≈20% of the total neurons
were siGLO positive; Supplementary Figures S2B–D). Although
some green dots seemed to be located at the extracellular
space, the majority of siGLO staining was located inside the
different cell types, suggesting that most of the siRNA used is
efficiently taken up by the cells (Supplementary Figures S2B,C).
Transfection with siGLO neither induced significant changes in
neuronal density nor affected the number of apoptotic neurons
3 h and 30 min after transfection (Supplementary Figure S2A).
The same was true in terms of affecting microglial density.
However, a small decrease in the astrocytic population was
observed. These data indicate that Glial-Mag method not only
efficiently transfects cortical microglia cultures but can also be
FIGURE 3 | Analysis of the effect of TREM2 knockdown over the phagocytic
and inflammatory responses and over the expression of other TREM family
members. (A) Representative dot blots comparing the phagocytic response
for tetramethylrhodamine (TAMRA)-labeled neuronal debris (TAMRA-ND)
between siNT and siRNA TREM2 treated cells in mouse. (B) Quantitative
analysis of phagocytosis normalized to siNT TAMRA-ND treated cells in
mouse. (C) Effect of TREM2 knockdown over Nos2, Il-1β and Tnf-α gene
expression upon LPS treatment (8 h; 10 ng/ml) in mouse. (D) Analysis of
TREM2 knockdown on the expression of other TREM family members
(TREM2, TREM1, TREML1 and TREML2) in mouse. Results are presented as
mean ± SD. Data are from three (B,C) and five (D) independent experiments.
All analyses were performed using two-tailed Welch’s t test. n.s stands for
non-significant. ∗P < 0.05 and ∗∗∗P < 0.001 and n.s stands for
non-significant.
used to transfect neuronal/glia mixed cultures without greatly
affecting the survival of neurons and glial cells.
To test whether this transfection protocol affects the
inflammatory response of microglia, we quantified the levels
of IL-6, a pro-inflammatory cytokine, in the media of the
transfectedmicroglial cells. No statistical difference was observed
in the release of IL-6 into the media between naïve (untreated)
and siNT-treated cells (Figure 2E). Furthermore, there was also
no difference in the IL-6 production of naïve and siNT cells
subsequently exposed to LPS (10 ng/ml) for 8 h, indicating that
this transfection method does not either inhibit or prime the
inflammatory response in these cells.
Functional Analysis of TREM2 Knockdown
Once we had established that our system does not have an impact
over the inflammatory response, we next assessed the effect of
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 September 2018 | Volume 12 | Article 313
Carrillo-Jimenez et al. siRNA Magnetofection in Primary Microglia
TREM2 knockdown over microglial function. Many studies have
focused on the effect that mutations or loss of TREM2 have
on microglial functions such as phagocytosis and inflammatory
response. For this reason, we measured the effect of the siRNA
of TREM2 on microglial phagocytosis of neuronal debris and
the inflammatory response induced by LPS. Transfection of the
microglia with siNT had little effect on phagocytosis of neuronal
debris compared to non-transfected cells (naïve) treated with
neuronal debris (Supplementary Figure S3A), consistent with
no effect on inflammatory activation (Figure 2). In contrast, we
found that knockdown of TREM2 caused a small but statistically
significant increase in microglial phagocytosis of neuronal debris
in mice (Figures 3A,B) and in rats (Supplementary Figures
3B–D) compared to siNT cells treated with neuronal debris cells.
Regarding the inflammatory response, we found that knockdown
of TREM2 reduced NOS2 expression of LPS-activated microglia
in mice, while TNF-α and IL-1β expression levels remained
unaltered (Figure 3C).
Some in vivo studies have shown that the knock down
of TREM2 expression lead to an artifactual increase in the
expression of TREML1 (Kang et al., 2018a), which hinders
the interpretation of TREM2 knockdown effects. We assessed
whether TREM2 knockdown in our study was associated
with a deregulation in the expression levels of other TREM
family members. We analyzed the expression of TREM1,
TREML1 and TREML2 by RT-qPCR. Our results demonstrated
that TREM2 knockdown using Glial-Mag method does not
induce a deregulation on the levels of expression of other
members of the TREM family (Figure 3D).
DISCUSSION
In this study, we present a simple method for successfully deliver
siRNA and knockdown of gene expression in primary microglia
based on binding of the siRNA to magnetic nanoparticles and
magnet-induced penetration of the cells. This method does not
require specific training or the use of specialized equipment for
knocking down the expression of different targets. We observe
with our method a high delivery rate (83%–93% of cells), even
using a 3 h and 30 min incubation with the siGLO probe.
Furthermore, we found that by using this method we can deliver
enough siRNA to induce a 60% knockdown of TREM2 and
CD33 in mice and 40% knockdown of TREM2 in rats 48 h
after transfection. An additional advantage of this transfection
method is the low toxicity and non-priming effect over the
inflammatory response in the cultures. The lack of priming effect
will providemore trustworthy data based only on the knockdown
of our target gene and not due to an artifact generated by
the methodology employed (as in the case discussed in Kang
et al., 2018a). Our results demonstrated that the reduction in
TREM2 expression observed after 48 h of transfection does
not induce a deregulation in the expression levels of other
TREM-related family members. These data correlate with other
in vivo studies in which the authors did not find a deregulation
of TREML1 in the original TREM2 knock out mice line
(Turnbull et al., 2006) or TREM2 knock out mice generated by
CRISPR/Cas9 technology (Kang et al., 2018a).
When using mixed neuronal-glial cultures, we found that this
method does not distinguish between microglia, neurons and
astrocytes, as siGLO entered all cell types in these cultures. This
is a disadvantage if aiming to target specifically microglia, but an
advantage if wanting to target all cells. However, it is important to
highlight that 80% of microglial cells incorporated siGLO, while
astrocytes and neurons exhibited lower rates of siGLO uptake.
In this article, we assessed the effect of knocking down
TREM2 on different aspects of microglial biology. There is some
controversy in the literature about what role plays TREM2 in
the control of different aspects of microglia biology, including
the control of the inflammatory and phagocytic responses.
While several reports support the idea that TREM2 acts as
anti-inflammatory protein whose total depletion or mutation
(for instance R47H) promotes a proinflammatory response and
reduces the phagocytic response, other reports demonstrate
the opposite (Li and Zhang, 2018). These studies suggest that
TREM2 has direct and indirect actions thatmay be contradictory.
We found that partial knockdown of TREM2 expression caused
a small (but statistically significant) increase in phagocytosis of
neuronal debris in both mice and rats and a small decrease
in LPS-induced NOS2 expression in mice. Our results may
differ from other reports published by others because of the
level of TREM2 depletion in the system (partial rather than
total). Our results are in concordance with those for mice
lacking one of the two TREM2 alleles (Ulrich et al., 2014),
where there was little or no change in inflammatory markers,
but a tendency for reduced NOS2 expression. Note that AD
is associated with loss of function mutations in only one
TREM2 gene, whereas loss-of-function in both TREM2 genes
results in a different disease: Nasu-Hakola disease. Thus, in
principle, partial knockdown of TREM2 may give a better
idea of microglial phenotype resulting from the AD-associated
mutations in TREM2. Although TREM2 is known to mediate
microglial phagocytosis of neuronal debris (Kawabori et al.,
2015), microglia have several other phagocytic receptors, and loss
of TREM2 is known to change the expression of a wide range of
microglial genes that might in principle account for our finding
of a small increase in microglial phagocytosis of neuronal debris.
In conclusion, we consider that this easy method will allow
many researchers to delve deeper into microglia mechanistic
studies of many aspects of microglia biology using primary
microglia cell cultures.
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